D3 Bio
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $108M
Overview
A data-driven biotech developing novel biologics for cancer and autoimmune diseases through patient-centric translational research.
OncologyImmunology
Technology Platform
Utilizes a data-driven, translational research platform that starts with human disease biology to identify novel targets and design optimized antibody therapeutics.
Funding History
1Total raised:$108M
Venture$108M
Opportunities
Its patient-centric, data-driven discovery model could yield first-in-class biologics with high response rates in defined populations.
Risk Factors
As an early-stage company with undisclosed assets, it carries high pipeline risk and faces significant challenges in translating its research approach into clinical success.
Competitive Landscape
Enters a highly competitive field for antibody therapies dominated by large biopharma, requiring truly novel biology or superior molecule engineering to stand out.